The trial is for a prostate cancer treatment.
Biocancell Therapeutics Ltd. (TASE:BICL) has completed a Phase I clinical trial for its prostate cancer treatment. The trial is for US Food and Drug Administration (FDA) registration. The company said that it had not yet received the final report on the trial, but preliminary data enabled it to assess that the trial achieved its goals to test the drug’s safety, to determine the recommended dosage, and to obtain indications about its toxicity.
Phase I trials of cancer drugs are conducted on patients, not healthy persons, because of the side effects characteristic even of good treatments. Trials are conducted on severely ill patients who have not responded to other treatments. Biocancell’s trial included 18 patients; patients who responded well to the treatment can opt to continue the trial for up to nine months. Other after this period will it be possible to report the full results of the trial.
The preliminary results were enough for Biocancell to apply to the FDA to conduct a Phase IIb trial, which the company hopes to begin by the end of the year. Biocancell CEO Avi Barak said that the company had sufficient cash to complete this trial.
Published by Globes [online], Israel business news - www.globes.co.il - on August 8, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007